Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Non-phase study NCT06896799

Determining the Effect of Food Ordering on Blood Glucose In Gestational Diabetes Mellitus (DEFI-GDM)

Determining the Effect of Food Ordering on Blood Glucose In Gestational Diabetes Mellitus (DEFI-GDM) — Recruiting • Non-phase study • Diabetes / Metabolic • NCT06896799.

📅 17 Apr 2026 ⏱ 3 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT06896799
Sponsor
Queen's University, Belfast
Start
2025-12-11
ClinicaliQ Trial Snapshot
  • Determining the Effect of Food Ordering on Blood Glucose In Gestational Diabetes Mellitus (DEFI-GDM) — Recruiting • Non-phase study • Diabetes / Metabolic • NCT06896799.
  • What is being tested: The trial investigates whether the order of macronutrient consumption (carbohydrates, proteins, fats) during meals affects postprandial blood glucose levels in women with gestational diabetes mellitus, comparing different eating sequences.
  • Patient eligibility overview: The study enrolls women diagnosed with gestational diabetes mellitus during pregnancy who require dietary or pharmacological management; specific inclusion criteria typically include confirmed GDM diagnosis and ability to comply with structured meal protocols.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The goal of this clinical trial is to determine whether the sequence of macronutrient consumption affects post-prandial glycaemia in women with gestational diabetes mellitus. The main questions it aims to answer are: * The difference in the magnitude of postprandial rise in blood glucose between the two test meals. * The difference in the magnitude of postprandial change in serum levels of gut hormones between the two test meals. * The difference in mean change in pre-post ingestion satiety scores between the two test meals. * The difference in 24…

Eligibility Snapshot
  • : * Pregnant women with gestational diabetes mellitus * Aged 18-50 years old

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Gestational Diabetes: Diagnosis and Treatment (NICE NG3)
Diabetes / Metabolic · 27 Mar 2026
Perform a 2-hour 75 g OGTT between 24–28 weeks in women with GDM risk factors; diagnose GDM if fasting glucose ≥5.6 mmol/L…
View guideline →
Guideline
Type 1 Diabetes in Adults: Diagnosis and Management (NICE NG17)
Diabetes / Metabolic · 25 Mar 2026
Offer multiple daily injection (MDI) basal-bolus insulin regimen as first-line treatment for all adults with type 1 diabetes, with continuous subcutaneous insulin…
View guideline →
Guideline
Non-Alcoholic Fatty Liver Disease: Assessment and Management (NICE NG49)
Diabetes / Metabolic · 27 Mar 2026
Use FIB-4 or NAFLD Fibrosis Score in primary care to stratify fibrosis risk in adults with metabolic risk factors (type 2 diabetes,…
View guideline →
Guideline
Obesity: Identification, Assessment and Management (NICE CG189)
Diabetes / Metabolic · 27 Mar 2026
Use BMI thresholds to identify obesity (≥30 kg/m² in adults; ≥27.5 kg/m² in Asian populations) and offer structured first-line weight loss interventions…
View guideline →
Clinical Brief
Why weight-loss jabs work better for some people than others
Diabetes / Metabolic · BBC Health · 10 Apr 2026
Genetic variations in appetite and digestion genes predict differential weight-loss responses to GLP-1 receptor agonists (Wegovy, Mounjaro), suggesting personalised medicine approaches may…
View brief →
Clinical Brief
Insulin pumps and continuous glucose monitoring (CGM) equipment: guidance for users on reporting suspected adverse incidents and safety concerns to the MHRA’s Yellow Card scheme
Diabetes / Metabolic · MHRA · 24 Oct 2024
We ask healthcare professionals to support new guidance for users of diabetes management equipment, their families, care givers and representatives. This update…
View brief →